![]() |
|
|
Vol. 300, Issue 1, 157-161, January 2002
Department of Pharmacology, University of Michigan Medical School,
Ann Arbor, Michigan
Opioid agonists acting at their receptors alter
intracellular events by initiating activation of various types of Gi/Go
proteins. This can be measured by the binding of the stable GTP analog
[35S]guanosine-5'-O-(3-thio)triphosphate
([35S]GTP
S). In this study agonist efficacy is defined
by the degree to which an opioid stimulates the binding of
[35S]GTP
S. This allows for a definition of full and
partial agonists; a full agonist causing a greater stimulation of
[35S]GTP
S binding than a partial agonist. The
hypothesis that the rate of agonist-stimulated
[35S]GTP
S binding is dependent upon agonist efficacy
was tested using membranes from C6 glioma cells expressing µ- or
-opioid receptors. At maximal concentrations the rate of
agonist-stimulated [35S]GTP
S binding followed the
efficacy of µ-agonists in stimulating [35S]GTP
S
binding, i.e.,
[D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin > morphine > meperidine > butorphanol > nalbuphine. At submaximal concentrations of µ- or
-full agonists the
[35S]GTP
S association rate was also reduced, such that
the rate of [35S]GTP
S binding correlated with the
extent of [35S]GTP
S bound, whether this binding was
stimulated by a full agonist or a partial agonist. Agonists also
stimulated [35S]GTP
S dissociation, showing that
binding of this stable nucleotide was reversible. Comparison of the
-agonists
[D-Ser2,Leu5]-enkephalin-Thr and
(±)-4-((
-R*)-
-((2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxylbenzyl)-N,N-diethylbenzamide, a compound with slow dissociation kinetics, showed the measured rate of
G protein activation was not influenced by the agonist switching
between receptors. The results are consistent with the idea that the
active state(s) of the receptor induced by full or partial agonists is
the same, but the number of activated receptors determines the rate of
G protein activation.
This article has been cited by other articles:
![]() |
M. J. Clark, J. J. Linderman, and J. R. Traynor Endogenous Regulators of G Protein Signaling Differentially Modulate Full and Partial {micro}-Opioid Agonists at Adenylyl Cyclase as Predicted by a Collision Coupling Model Mol. Pharmacol., May 1, 2008; 73(5): 1538 - 1548. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-X. Li, G. L. Becker, J. R. Traynor, Z.-H. Gong, and C. P. France Thienorphine: Receptor Binding and Behavioral Effects in Rhesus Monkeys J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 227 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Raehal, J. J. Lowery, C. M. Bhamidipati, R. M. Paolino, J. R. Blair, D. Wang, W. Sadee, and E. J. Bilsky In Vivo Characterization of 6{beta}-Naltrexol, an Opioid Ligand with Less Inverse Agonist Activity Compared with Naltrexone and Naloxone in Opioid-Dependent Mice J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1150 - 1162. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zollner, M. A. Shaqura, C. P. Bopaiah, S. Mousa, C. Stein, and M. Schafer Painful Inflammation-Induced Increase in {micro}-Opioid Receptor Binding and G-Protein Coupling in Primary Afferent Neurons Mol. Pharmacol., August 1, 2003; 64(2): 202 - 210. [Abstract] [Full Text] [PDF] |
||||